Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection

Advances in Experimental Medicine and Biology

Volumn 527, Issue , 2003, Pages 317-323

  Neurauter, Gabriele ^a,c   Zangerle, Robert ^b   Widner, Bernhard ^a   Quirchmair, Gisela ^b   Sarcletti, Mario ^b   Fuchs, Dietmar ^a,c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; KYNURENINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRYPTOPHAN; VIRUS RNA;

AMINO ACID BLOOD LEVEL; CELL COUNT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; T LYMPHOCYTE; TRYPTOPHAN METABOLISM; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 1042268015     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0135-0_35     Document Type: Conference Paper

References (34)

1. M.W. Taylor, G.S. Feng, Relationship between interferon-γ, indoleamine 2, 3-dioxygenase, and tryptophan catabolism, FASEB J. 5, 2516-2522 (1991).
2. E.R. Pfefferkorn, Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan, Proc. Natl. Acad. Sci. USA 81, 908-912 (1984).
3. L.M. de la Maza, E.M. Peterson, Dependence of the in vitro antiproliferative activity of recombinant human gamma-interferon on the concentration of tryptophan in culture media, Cancer Res. 48, 346-350 (1988).
4. Y. Ozaka, M.P. Edelstein, D.S. Duch, Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma, Proc. Natl. Acad. Sci. USA 85, 1242-1246 (1988).
5. D.H. Munn, E. Shafizadeh, J.T. Attwood, I. Bondarev, A. Pashine, A.L. Mellor, Inhibition of T-cell proliferation by macrophage tryptophan catabolism, J. Exp. Med. 189, 1663-1672 (1999).
6. P. Hwu, M.X. Du, R. Lapointe, M. Do, M.W. Taylor, H.A. Young, Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation, J. Immunol. 164, 3596-3599 (2000).
7. A.L. Mellor, D.H. Munn, Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol. Today 20, 469-473 (1999).
8. B. Widner, G. Weiss, D. Fuchs, Tryptophan degradation to control T-cell responsiveness, Immunol. Today 21, 250 (2000).
9. A.S. Fauci, Host factors and the pathogenesis of HIV-induced disease, Nature 384, 529-354 (1996).
10. D. Fuchs, A. Hausen, G. Reibnegger, et al., Interferon-γ concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J. Acquir. Immune Defic. Syndr. 2, 158-162 (1989).
11. D. Fuchs, T.J. Spira, A. Hausen, G. Reibnegger, E.R. Werner, G. Werner-Felmayer, et al., Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection, Clin. Chem. 35, 1746-1749 (1989).
12. C.A. Sabin, H. Devereux, A.N. Phillips, G. Janossy, C. Loveday, C.A. Lee, Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men, AIDS 12, 1347-1352 (1998).
13. Z. Liu, W.G. Cumberland, L.E. Hultin, A.H. Kaplan, R. Detels, J.V. Giorgi, CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18, 332-340 (1998).
14. J.L. Fahey, J.M. Taylor, B. Manna, P. Nishanian, N. Aziz, J.V. Giorgi, et al., Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements, AIDS 12, 1581-1590 (1998).
15. D. Fuchs, G.M. Shearer, R.N. Boswell, M. Clerici, G. Reibnegger, E.R. Werner, et al., Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production, Clin. Exp. Immunol. 80, 44-48 (1990).
16. E.R. Werner, D. Fuchs, A. Hausen, H. Jaeger, G. Reibnegger, G. Werner-Felmayer, et al., Tryptophan degradation in patients infected by human immunodeficiency virus, Biol. Chem. Hoppe Seyler 369, 337-340 (1988).
17. D. Fuchs, A.A. Moeller, G. Reibnegger, E.R. Werner, G. Werner-Felmayer, M.P. Dierich, H. Wachler, Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection, Immunol. Lett. 28, 207-211 (1990).
18. M.P. Heyes, B.J. Brew, A. Martin, R.W. Price, A.M. Salazar, J.J. Sidtis, et al., Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status, Ann. Neurol. 29, 202-209 (1991).
19. M. Gisslen, M. Larsson, G. Norkrans, D. Fuchs, H. Wachter, L. Hagberg, Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection, AIDS Res. Hum. Retroviruses 10, 947-951 (1994).
20. M. Huengsberg, J.B. Winer, M. Gompels, R. Round, J. Ross, M. Shahmanesh, Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients, Clin. Chem. 44, 858-862 (1998).
21. M.P. Look, M. Altfeld, K.A. Kreuzer, R. Riezler, S.P. Stabler, R.H. Allen, T. Sauerbruch, J.K. Rockstroh, Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease, AIDS Res. Hum. Retroviruses 16, 1215-1221 (2000).
22. R. Zangerle, B. Widner, G. Quirchmair, G. Neurauter, M. Sarcletti, D. Fuchs, Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection, Clin. Immunol. (in press).
23. B. Widner, E.R. Werner, H. Schennach, H. Wachter, D. Fuchs, Simultaneous measurement of serum tryptophan and kynurenine by HPLC, Clin. Chem. 43, 2424-2426 (1997).
24. D. Fuchs, A.A. Möller, E. Stöckle, G. Reibnegger, E.R. Werner, H. Wachter, Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and neurologic/psychiatric symptoms, J. Acquir. Immune. Defic. Syndr. 3, 873-876 (1990).
25. B. Widner, M. Ledochowski, D. Fuchs, Interferon gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences, Curr. Drug Metab. 1, 193-204 (2000).
26. B. Widner, B. Wirleitner, G. Baier-Bitterlich, G. Weiss, D. Fuchs, Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch. Immunol. Ther. Exp. (Warsz) 48, 251-258 (2000).
27. D. Fuchs, A. Hausen, G. Reibnegger, E.R. Werner, M.P. Dierich, H. Wachter, Neopterin as a marker for activated cell-mediated immunity: application in HIV infection, Immunol. Today 9, 150-155 (1988).
28. A. Diez-Ruiz, G.P. Tilz, R. Zangerle, G. Baier-Bitterlich, H. Wachter, D. Fuchs, Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis, Eur. J. Haematol. 54, 1-8 (1995).
29. F.A. Moreno, C. McGavin, T.P. Malan, A.J. Gelenberg, G.R. Heninger, A.A. Mathe, P.L. Delgado, Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling technique, Int. J. Neuropsychopharmacol. 3, 277-283 (2000).
30. S. Suarez, L. Baril, B. Stankoff, M. Khellaf, B. Dubois, C. Lubetzki, F. Bricaire, J.J. Hauw, Outcome of patients with HIV-1-related cognitive impairment on JJ highly active antiretroviral therapy. AIDS 15, 195-200 (2001).
31. H.E. Gendelman, J. Zheng, C.L. Coulter, A. Ghorpade, M. Che, M. Thylin, R. Rubocki, Y. Persidsky, F. Hahn, J. Reinhard, Jr., S. Swindells, Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia, J. Infect. Dis. 178, 1 1000-1007 (1998).
32. F.K. Judd, A.M. Cockram, A. Komiti, A.M. Mijch, J. Hoy, R. Bell, Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study, Aust. N. Z. J. Psychiatry 34, 1015-1021 (2000).
33. R. Zangerle, G. Reibnegger, H. Wachter, D. Fuchs, Weight loss in HIV-1 infection is associated with immune activation, AIDS 7, 175-181 (1993).
34. H. Denz, B. Orth, G. Weiss, R. Herrmann, P. Huber, H. Wachter, D. Fuchs, Weight loss in patients with hematological neoplasias is associated with immune system stimulation, Clin. Investig. 71, 37-41 (1993).